A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension has missed its primary endpoint, triggering a 77% crash in the biotech’s share price.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
A phase 3 study of Gossamer Bio’s seralutinib in pulmonary arterial hypertension has missed its primary endpoint, triggering a 77% crash in the biotech’s share price.